Last reviewed · How we verify
NCT04686045
Stroke Prevention in Atrial Fibrillation Patients Between 2004 and 2020
trial testing observational study in Atrial Fibrillation; Stroke Prevention in 10,000 participants. Status unknown.
1 March 2021
Quick facts
| Lead sponsor | Jan Kochanowski University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000 |
| Start date | 1 January 2021 |
| Primary completion | 1 March 2021 |
| Estimated completion | 1 May 2021 |
| Sites | 2 locations across Poland |
Drugs / interventions tested
- observational study — full drug profile →
Conditions studied
- Atrial Fibrillation; Stroke Prevention — all drugs for Atrial Fibrillation; Stroke Prevention →
Sponsor
Jan Kochanowski University
Who can join
18 and older, any sex, with Atrial Fibrillation; Stroke Prevention. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prevention of thromboembolic complications is an important part in the management of patients with atrial fibrillation (AF). European and American guidelines recommend the use of non-vitamin K antagonist oral anticoagulants (NOACs) over therapy with vitamin K antagonists (VKA) in most AF patients. The number of patients treated with NOACs has increased significantly during the last few years. In the primary randomized controlled trials leading to their approval, compared to warfarin, NOACs were shown to be either noninferior or superior for stroke prevention in AF, with similar or reduced rates of bleeding, especially intracranial haemorrhage. The aim of this study was to assess the frequency of oral anticoagulants using, espescially apixaban, dabigatran, and rivaroxaban, and the predictors of their prescription in a group of hospitalised patients with AF.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04686045
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of observational study
Trials testing the same drug.
- NCT07497139 — Sepsis Induced Myocardial Injury in Critically Ill Children · not yet recruiting
- NCT07379567 — BREVOC Study: Exhaled VOCs for High-Risk Chest Pain in the ED · not yet recruiting
- NCT07391007 — Integrated Clinical-molecular Risk Stratification to Early Recurrence in Colorectal Liver Metastases · not yet recruiting
- NCT07372183 — Wound Healing Following Extraction and Ridge Preservation in Smokers and Non-smokers · not yet recruiting
- NCT07310186 — Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy · not yet recruiting
Other Jan Kochanowski University trials
Trials by the same sponsor.
- NCT06815822 — Prevention of Postoperative Hernias in Emergency Surgery · recruiting
- NCT05652322 — Prolonged Intravenous Therapy Versus Early Initiation of an Oral Loop Diuretic in Decompensated Heart Failure · Phase 2, PHASE3 · withdrawn
- NCT04419012 — Polish Atrial Fibrillation (POL-AF) Registry · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04686045 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jan Kochanowski University
- Last refreshed: 26 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04686045.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing